01 9Kalydeco
02 5Orkambi
03 2Symdeko
04 3Symdeko/Symkevi
05 2Trikafta
06 3Trikafta/Kaftrio
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 991
2018 Revenue in Millions : 1,008
Growth (%) : -2
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2019 Revenue in Millions : 1,418
2018 Revenue in Millions : 769
Growth (%) : 84
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 1,176
2018 Revenue in Millions : 1,262
Growth (%) : -7
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2019 Revenue in Millions : 420
2018 Revenue in Millions : 0
Growth (%) : New launch
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 629
2019 Revenue in Millions : 1,418
Growth (%) : -56
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 908
2019 Revenue in Millions : 1,176
Growth (%) : -23
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 3,864
2019 Revenue in Millions : 420
Growth (%) : 820
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 803
2019 Revenue in Millions : 991
Growth (%) : -19
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 684
2020 Revenue in Millions : 803
Growth (%) : -17
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 5,697
2020 Revenue in Millions : 3,864
Growth (%) : 32
LOOKING FOR A SUPPLIER?